1. Scrip

Can Axovant's RVT-1 Redeem 5HT6 Class After Lundbeck's Idalopirdine Failure?

 
• By Emily Hayes

Lundbeck says it remains committed to developing new Alzheimer's disease drugs with a variety of different mechanisms, after the unsurprising failure of 5HT6 antagonist idalopirdine in two more Phase III studies.

Human brain illustrated with millions of small nerves - Conceptual 3d render

The failure of Lundbeck Inc./Otsuka Pharmaceutical Co. Ltd.'s idalopirdine in two more Phase III trials is yet another blow for Alzheimer's disease research and for serotonin 5-HT6 antagonists, though there is still some reason to hold off on death rites for the drug class until Axovant Sciences Ltd.'s intepirdine (RVT-101) Phase III read-out later this year.

Lundbeck/Otsuka announced the failure of the Phase III STARBEAM and STARBRIGHT studies of idalopirdine in moderate to severe Alzheimer's disease on Feb. 8 and said the data do not support a regulatory approval. Idalopirdine had already failed in the Phase III STARSHINE study in September 2016

More from Neurological

More from Therapy Areas

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.